Avenue Therapeutics (ATXI) Competitors $2.00 -0.01 (-0.50%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends ATXI vs. EDSA, AKTX, INAB, NRXP, KZIA, AIM, PMCB, SLGL, NLSP, and WENAShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Edesa Biotech (EDSA), Akari Therapeutics (AKTX), IN8bio (INAB), NRx Pharmaceuticals (NRXP), Kazia Therapeutics (KZIA), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Sol-Gel Technologies (SLGL), NLS Pharmaceutics (NLSP), and ANEW Medical (WENA). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Edesa Biotech Akari Therapeutics IN8bio NRx Pharmaceuticals Kazia Therapeutics AIM ImmunoTech PharmaCyte Biotech Sol-Gel Technologies NLS Pharmaceutics ANEW Medical Edesa Biotech (NASDAQ:EDSA) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Do analysts rate EDSA or ATXI? Edesa Biotech currently has a consensus price target of $21.00, indicating a potential upside of 895.26%. Given Edesa Biotech's higher possible upside, research analysts clearly believe Edesa Biotech is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EDSA or ATXI? In the previous week, Avenue Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Avenue Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 beat Avenue Therapeutics' score of -1.06 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avenue Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Is EDSA or ATXI more profitable? Edesa Biotech's return on equity of -137.95% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -137.95% -97.48% Avenue Therapeutics N/A -471.57%-296.50% Which has more risk & volatility, EDSA or ATXI? Edesa Biotech has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Does the MarketBeat Community favor EDSA or ATXI? Avenue Therapeutics received 120 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 60.25% of users gave Avenue Therapeutics an outperform vote. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Avenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% Which has preferable earnings & valuation, EDSA or ATXI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$8.37MN/AN/AAvenue TherapeuticsN/AN/A-$10.38M$18.350.11 Do institutionals & insiders have more ownership in EDSA or ATXI? 5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryEdesa Biotech beats Avenue Therapeutics on 8 of the 11 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.82M$6.52B$5.11B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio0.117.36108.8915.88Price / SalesN/A366.511,233.2287.15Price / CashN/A52.5939.9336.27Price / Book2.3310.176.946.36Net Income-$10.38M$153.36M$119.18M$226.00M7 Day Performance5.82%-1.61%-1.36%-0.02%1 Month PerformanceN/A-7.15%-3.27%1.95%1 Year Performance-86.42%31.68%32.40%27.80% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics1.4263 of 5 stars$2.00-0.5%N/A-86.7%$3.82MN/A0.114Negative NewsGap DownEDSAEdesa Biotech3.1614 of 5 stars$2.11-4.1%$21.00+895.3%-27.9%$6.86MN/A0.0020Gap DownAKTXAkari TherapeuticsN/A$1.24-15.6%N/A-55.0%$15.07MN/A0.009Analyst ForecastNews CoverageHigh Trading VolumeINABIN8bio3.2176 of 5 stars$0.32flat$7.75+2,321.9%-62.8%$14.97MN/A-0.4320NRXPNRx Pharmaceuticals2.0075 of 5 stars$1.23+1.7%$31.50+2,461.0%-96.1%$14.87MN/A-0.572KZIAKazia Therapeutics1.8873 of 5 stars$5.53-1.4%$20.00+261.7%-26.9%$14.60M$1.51M0.0012AIMAIM ImmunoTech1.7806 of 5 stars$0.21+5.0%$3.00+1,317.1%-52.0%$13.49M$200,000.00-0.4520News CoverageHigh Trading VolumePMCBPharmaCyte Biotech0.651 of 5 stars$1.75+1.7%N/A-21.1%$13.44MN/A2.732SLGLSol-Gel Technologies3.6414 of 5 stars$0.48+6.7%$5.00+952.4%-68.5%$13.24M$1.55M-1.4050News CoverageGap DownNLSPNLS Pharmaceutics1.2189 of 5 stars$3.37+2.4%N/A+623.1%$12.85MN/A0.006WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap Up Related Companies and Tools Related Companies Edesa Biotech Alternatives Akari Therapeutics Alternatives IN8bio Alternatives NRx Pharmaceuticals Alternatives Kazia Therapeutics Alternatives AIM ImmunoTech Alternatives PharmaCyte Biotech Alternatives Sol-Gel Technologies Alternatives NLS Pharmaceutics Alternatives ANEW Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts